相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
Tinya Abrams et al.
CLINICAL CANCER RESEARCH (2018)
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Julie Delyon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
JAK-ing up the Response to KIT Inhibition
Jessica Yang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Adrian M. Seifert et al.
CLINICAL CANCER RESEARCH (2017)
Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma
Winnie S. Liang et al.
GENOME RESEARCH (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A precision therapy against cancers driven by KIT/PDGFRA mutations
Erica K. Evans et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A Phase 2 Trial of Dasatinib in Patients With Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)
Kevin Kalinsky et al.
CANCER (2017)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J. Guo et al.
ANNALS OF ONCOLOGY (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D. Carvajal et al.
CLINICAL CANCER RESEARCH (2015)
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
Kaori Sakaizawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2015)
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Lisa Christiansson et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
A. Hunter Shain et al.
NATURE GENETICS (2015)
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)
Su Jin Lee et al.
ONCOLOGIST (2015)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
Anna Kreutzman et al.
ONCOIMMUNOLOGY (2014)
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Sylvie Rusakiewicz et al.
CANCER RESEARCH (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy
Heikki Joensuu et al.
ANNUAL REVIEW OF MEDICINE, VOL 63 (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor et al.
CLINICAL CANCER RESEARCH (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Melanoma genome sequencing reveals frequent PREX2 mutations
Michael F. Berger et al.
NATURE (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Michael Krauthammer et al.
NATURE GENETICS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Yan Kong et al.
CLINICAL CANCER RESEARCH (2011)
KIT as a Therapeutic Target in Metastatic Melanoma
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
Scott E. Woodman et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman et al.
BLOOD (2010)
Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
Akane Tsujimura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Lck is a key target of imatinib and dasatinib in T-cell activation
K. C. Lee et al.
LEUKEMIA (2010)
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
Despina Handolias et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance
HW Wang et al.
BLOOD (2005)
Signal transduction via the stem cell factor receptor/c-Kit
L Rönnstrand
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
